Skip to main content

MDS Extends Offer to Buy Molecular Devices to Meet Foreign Regulations

NEW YORK (GenomeWeb News) – MDS has extended to March 19 its offer to buy Molecular Devices in order to give it additional time to meet “certain foreign regulatory conditions,” MDS said today.

The company still expects the deal to close within the next few weeks. It is in the process of meeting regulatory requirements in and in , MDS spokesperson Catherine Melville told GenomeWeb News.  

As GenomeWeb News previously in January, the companies had agreed to a deal under which MDS would buy Molecular Devices for $615 million in cash, or $35.50 a share for all of Molecular Devices’ common stock.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.